Clinical Trial: QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma

U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06822985) titled 'QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma' on Feb. 07.

Brief Summary: This is a phase I trial to assess the safety and preliminary efficacy of QL1706 in Treating Advanced Hepatocellular Carcinoma Patients refractory to prior immunotherapy.

Study Start Date: Feb. 01

Study Type: INTERVENTIONAL

Condition: HCC - Hepatocellular Carcinoma

Intervention: DRUG: QL1706

Drug: QL1706 7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Wan-Guang Zhang

Information provided by (Responsible Party): Wan-Guang Zhang, Tongji Hospital

Pub...